---
title: "Genelux Corporation (GNLX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/GNLX.US.md"
symbol: "GNLX.US"
name: "Genelux Corporation"
industry: "生物技術"
---

# Genelux Corporation (GNLX.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.genelux.com](https://www.genelux.com) |

## Company Profile

Genelux Corporation 是一家臨床階段的生物制藥公司，專注于開發針對患有侵襲性和/或難以治療的實體腫瘤類型患者的溶瘤病毒免疫療法。其主要產品候選藥物是 Olvi-Vec，這是一種專有的改良牛痘病毒株，適用于卵巢癌和非小細胞肺癌的治療，以及液體或實體腫瘤、闌尾癌、結直腸癌和胃癌、其他婦科惡性腫瘤和腹膜間皮瘤。該公司與 Newsoara BioPharma Co. Ltd.簽訂了許可協議

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:14.000Z

**Overall: D (0.76)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 271 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -15.23% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 6.16 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 114.48M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 0.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -123.35% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -15.23% | D |
| Total Assets YoY | -37.95% | E |
| Net Assets YoY | -43.82% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 25.60% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Genelux Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-123.35%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-15.23%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-37.95%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-43.82%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "25.60%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯維 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.59 | 337/605 | - | - | - |
| PB | 6.16 | 332/605 | 8.50 | 5.27 | 3.65 |
| PS (TTM) | 10862.11 | - | 10862.11 | 10862.11 | 10862.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-12T05:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 83% |
| Overweight | 1 | 17% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.56 |
| Highest Target | 31.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/GNLX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/GNLX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/GNLX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.